SEC Form 4 · accession 0001209191-17-053302
Cidara Therapeutics, Inc. · CDTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew Onaitis
Officer — Gnrl Counsel, CFO & Secretary
Period of report
Sep 18, 2017
Accepted (ET)
Sep 19, 2017 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001610618
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 18, 2017 | A | 15,000 | $0.00 | A | 15,872 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF3,F4 | — | Sep 18, 2017 | M | 25,000 | A | — | — | Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F11/3rd of the total number of shares subject to the restricted stock unit shall vest on each December 31 of 2018, 2019 and 2020.
- F2Includes 872 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 19, 2017.
- F3Restricted stock units convert into common stock on a one-for-one basis.
- F4A portion of the shares vest upon the achievement of various clinical and corporate milestones.